Evaluating a new treatment for congenital protein C deficiency

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on the use of Freeze-dried Human Protein C Concentrate (TAK-662) to treat individuals with congenital protein C deficiency. Participants will receive intravenous injections of TAK-662 under routine clinical practice, and the study will monitor for any adverse events and the treatment's effectiveness over a period of up to 24 months. The study is conducted in Japan and aims to gather data on the safety and efficacy of this treatment in real-world settings.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\- All participants with congenital protein C deficiency who are administered with Freeze-dried Human Protein C Concentrate (TAK-662).

Exclusion Criteria:

\- None

Where it's running

• Takeda selected site
  Tokyo, Tokyo, Japan Recruiting

Study contacts

• Study coordinator: Takeda Contact
• Email: medinfoUS@takeda.com
• Phone: +1-877-825-3327

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Rusfertide in Japanese adults with polycythemia vera

  This study tests rusfertide in Japanese adults with polycythemia vera to see if it helps keep hematocrit under control and reduce the need for blood removal.

  Recruiting at 8 sites Phase 2 Takeda · Nagoya, Aichi-ken and 8 other locations · NCT07648030

• Long-term test of TAK-360 in people with narcolepsy or idiopathic hypersomnia

  This study tests TAK-360 over an extended period to see if it is tolerable for people with narcolepsy type 1, narcolepsy type 2, or idiopathic hypersomnia who completed an earlier TAK-360 trial.

  Recruiting at 33 sites Phase 2/3 Takeda · Chula Vista, California and 32 other locations · NCT07646678

• TAK-360 in adults with narcolepsy Type 1 with cataplexy

  This study tests TAK-360 versus placebo in adults with narcolepsy Type 1 to see if it is safe and tolerable.

  Recruiting at 9 sites Phase 2 Takeda · Redwood City, California and 17 other locations · NCT07633301

• Fruquintinib treatment in adults with metastatic colorectal cancer in Poland

  This study looks at whether taking fruquintinib by mouth after prior therapies helps adults with metastatic colorectal cancer in Poland live longer before the cancer progresses and overall survival, while also considering quality of life.

  Recruiting at 3 sites Takeda · Poznan, Greater Poland Voivodeship and 9 other locations · NCT07623174

• Elritercept vs. placebo for adults with myelofibrosis and anemia on ruxolitinib

  This study tests whether elritercept can improve anemia in adults with myelofibrosis who are taking ruxolitinib, compared with placebo.

  Recruiting at 11 sites Phase 3 Takeda · Gilbert, Arizona and 213 other locations · NCT07623161

• Mezagitamab for adults with late antibody-mediated rejection after kidney transplant

  Mezagitamab is being tested to see if it is safe and helps kidney transplant patients with late antibody-mediated rejection, compared with a placebo.

  Recruiting at 4 sites Phase 2 Takeda · Los Angeles, California and 34 other locations · NCT07613359

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.